Lipid metabolic enzymes (LME)

Lipid metabolic enzymes are a broad class of proteins that catalyze the synthesis, modification, and breakdown of lipids, including fatty acids, cholesterol, and phospholipids. These enzymes, such as HMG-CoA reductase, fatty acid synthase (FASN), and cyclooxygenases (COX), are essential for maintaining cellular membrane structure, energy storage, and the production of signaling molecules like prostaglandins (PubMed: 31507900). Dysregulation of these enzymatic pathways is central to the pathogenesis of metabolic syndrome, atherosclerosis, and nonalcoholic fatty liver disease (NIH: NBK542252). Furthermore, many cancers exploit lipid metabolic enzymes to support rapid membrane synthesis and pro-survival signaling (Nature Reviews Cancer: 10.1038/nrc.2016.71). Therapeutic strategies targeting these enzymes are well-established, exemplified by statins for cardiovascular disease and orlistat for obesity. Novel inhibitors of enzymes like acetyl-CoA carboxylase (ACC) and FASN are currently under investigation for the treatment of nonalcoholic steatohepatitis (NASH) and various malignancies (Journal of Lipid Research: 10.1194/jlr.R083014). Because these enzymes often represent rate-limiting steps in complex metabolic networks, they serve as high-value targets for drug development, though systemic modulation requires careful monitoring of liver and muscle safety.

Other names

Enzymes of lipid metabolismLipogenic enzymesLipolytic enzymesLipid-processing enzymes

Inhibition of specific enzymatic activities within lipid biosynthetic or catabolic pathways to restore lipid homeostasis or reduce pathological lipid accumulation.